Here, we report the TM5614 Phase II clinical trial on the use of the PAI‐1 inhibitor, TM5614 combined with a TKI for patients with CML not achieving MR4.5 with TKI treatment alone. The gene discussed is SERPINE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.